Bruker Corporation (BRKR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: declining revenue and margins, but optimistic cost-saving and market recovery plans for 2026. The Q&A highlights management's confidence in improving margins and order momentum, but also notes cautious growth in key segments and unclear guidance on some factors. The absence of new partnerships or shareholder return plans, coupled with mixed financial projections, supports a neutral sentiment.
Key Financial Performance
Fourth Quarter 2025 Revenue $977.2 million, approximately flat year-over-year. Organic revenue declined by 5.1%, with a 4.1% currency tailwind and 0.8% growth from M&A. Decline attributed to lower volume, additional tariff costs, and currency headwinds.
Fourth Quarter 2025 Non-GAAP Operating Margin 15.7%, down 240 basis points year-over-year. Decline due to lower revenue volume, unfavorable mix, tariffs, and currency headwinds, partially offset by cost and pricing actions.
Fourth Quarter 2025 Non-GAAP Diluted EPS $0.59, down from $0.76 in Q4 2024. Decline driven by lower revenue volume, unfavorable mix, and currency headwinds.
Fourth Quarter 2025 Free Cash Flow $207 million, strong performance after weaker cash flow earlier in 2025.
Full Year 2025 Revenue $3.44 billion, up 2.1% year-over-year. Organic revenue declined by 3.7%, with a 3.5% growth contribution from acquisitions and a 2.3% currency tailwind. Decline due to volume deleverage, currency, and tariff headwinds.
Full Year 2025 Non-GAAP Operating Margin 12.6%, down 280 basis points year-over-year. Decline due to M&A dilution, tariffs, currency headwinds, and lower volume.
Full Year 2025 Non-GAAP EPS $1.83, down from $2.12 in 2024. Decline attributed to M&A dilution, volume deleverage, and currency and tariff headwinds.
Full Year 2025 Free Cash Flow $230 million, highest in company history, driven by improved working capital performance.
BioSpin Group 2025 Revenue $879 million, mid-single-digit percentage decline. Decline due to fewer gigahertz NMR systems and weak biopharma revenues.
CALID Group 2025 Revenue $1.2 billion, high single-digit percentage growth. Growth driven by microbiology, infection diagnostics, and applied market security detection, offset by softness in mass spectrometry.
Bruker Nano 2025 Revenue $1.1 billion, low single-digit percentage decline. Decline due to ACA/GOV industrial market weakness, offset by growth in spatial biology and biopharma.
BEST Segment 2025 Revenue Mid-single-digit percentage decline. Decline due to soft superconducting demand for clinical MRI systems, partially offset by major multiyear orders for superconducting wire.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: Bruker launched innovative and competitive products at AGBT, AACR, and ASMS conferences in 2025. These products have seen strong initial demand, expected to drive revenue growth in 2026 and beyond.
Self-Driving Labs: Bruker announced next-gen automated and digitized self-driving labs at the SLAS conference in Boston, showcasing innovation in laboratory automation.
Geographic Revenue Distribution: Asia Pacific revenue grew in high single digits in Q4 2025, with double-digit growth in China. U.S. biopharma and industrial growth improved in the second half of 2025, while U.S. ACA/GOV remained weak.
Semiconductor Metrology: Strong order growth in semiconductor metrology tools, particularly in Q4 2025, driven by the AI boom and advanced packaging.
Cost-Saving Initiatives: Bruker exceeded its cost-saving target of $100-$120 million in 2025, contributing to expected operating margin expansion in 2026.
Revenue Backlog: Bruker starts 2026 with a solid backlog of over 7 months of revenue and strong bookings momentum.
Strategic Acquisitions: ELITech and Chemspeed showed mid- to high single-digit organic revenue growth in 2025, while NanoString orders grew double digits in Q4 2025.
Project Accelerate 3.0: Focus on expanding leadership in post-genomic disease research, drug discovery tools, and diagnostics. ELITech molecular diagnostics and WAVE platform for rapid AST are key highlights.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Academic Funding: Headwinds from academic funding in 2025 negatively impacted NanoString's performance and U.S. academic funding remains uncertain, posing risks to future revenue growth.
Tariffs and Currency Exchange Rates: Additional tariff costs and currency headwinds significantly impacted operating margins and EPS in 2025, with continued currency headwinds expected in 2026.
Supply Chain Disruptions: Delayed tariff offsets and unfavorable mix impacted margins, indicating ongoing supply chain challenges.
Geopolitical Risks: Geopolitical risks were mentioned as a factor that could impact future performance, though specific details were not provided.
Competitive Dynamics: Competitive pressures in diagnostics and research tools markets could impact revenue growth and market share.
China Market Decline: Revenue from China declined from 16-17% to under 14% of total revenue, reflecting challenges in this key market.
Gigahertz NMR Systems: Declines in gigahertz NMR system revenues due to fewer systems being delivered in 2025 and expected in 2026, impacting revenue.
ACA/GOV Market Weakness: Weakness in the U.S. ACA/GOV market persisted throughout 2025, with lingering uncertainty in 2026.
Volume Deleverage: Lower revenue volumes in 2025 led to operating margin declines, posing risks to profitability.
BEST Segment Performance: The BEST segment experienced mid-single-digit revenue declines in 2025 due to soft demand for superconducting MRI systems, though multiyear agreements may offset this in the future.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Bruker Corporation expects reported revenue growth of 4% to 5% for fiscal year 2026, with 1% to 2% organic revenue growth and a 1.5% contribution from acquisitions. Constant exchange rate revenue growth is projected at 2.5% to 3.5%.
Operating Margin: The company aims for a 250 to 300 basis points improvement in non-GAAP operating profit margin in 2026, despite a 50 basis points currency headwind. This includes 300 to 350 basis points of expected organic operating margin expansion driven by cost-saving initiatives.
Earnings Per Share (EPS): Non-GAAP EPS growth is projected at 15% to 17% for fiscal year 2026, with constant exchange rate EPS growth expected to be 23% to 25%.
Market Trends and Demand: Bruker anticipates improved demand in 2026 for its post-genomic discovery, translational, and diagnostic solutions, supported by a solid backlog of over 7 months of revenue and strong bookings momentum. The biopharma and industrial research markets are expected to recover, and semiconductor metrology orders are projected to drive stronger performance.
NIH Funding Impact: The fiscal year 2026 NIH budget has increased, which is expected to positively impact demand, although some uncertainty remains in the U.S. academic and government markets.
BEST Segment Performance: The BEST segment, which was a headwind in 2025, is expected to become a tailwind in 2026, supported by major multiyear agreements worth over $500 million.
Product Launches and Innovations: Recent product launches are expected to drive revenue growth in fiscal year 2026 and beyond. The company is focusing on expanding its leadership in post-genomic disease research, drug discovery tools, and diagnostics.
Quarterly Performance Expectations: Organic revenue is expected to decline in the mid-single digits in Q1 2026 due to a strong year-over-year comparison, with organic revenue growth resuming in Q2 2026 and continuing for the remainder of the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you talk about the cost initiatives focused on improving margins in 2026 and provide details on the $120 million reduction?
A:Frank Laukien explained that the company expects annualized cost initiatives to yield closer to $140 million or higher, with full effectiveness by Q3 2026. Gerald Herman added that operating margin growth will ramp significantly starting in Q2, with European-based cost actions taking effect in Q1 and Q2.
Q:What is the outlook for U.S. ACA/GOV customers and NIH funding?
A:Frank Laukien stated that U.S. ACA/GOV orders in Q4 were weak but are expected to improve slightly in the second half of 2026. NIH funding is expected to be flat or up 1%, with some limitations on multiyear grants. He remains cautious about growth rates in this segment.
Q:What gives you confidence in achieving higher margins in 2026 despite challenges in Q4 2025?
A:Frank Laukien mentioned that the company has already taken out the high end of $100 million to $120 million in costs and is implementing additional cost reductions. He also noted improvements in pricing and supply chain measures, which have longer lead times but are expected to contribute positively in 2026.
Q:How do you view revenue pacing through 2026, especially given the mid-single-digit decline expected in Q1?
A:Frank Laukien explained that easier year-over-year comparisons starting in Q2 and improving order momentum in segments like biopharma and industrial research will drive better performance in the remaining quarters of 2026. He expects organic growth rates to improve but not fully return to long-term growth rates until 2027.
Q:What are the assumptions for end markets like biopharma, semi, and microbiology in 2026?
A:Gerald Herman stated that biopharma is expected to grow in low single digits, semi in low single digits, and clinical/microbiology slightly stronger. Academic and government research is expected to be flat or slightly down, while industrial and applied markets are expected to be flat.
Q:What is the outlook for gross margins in 2026?
A:Gerald Herman confirmed that gross margins are expected to expand in 2026, driven by improved mix and recovery from tariff impacts. Frank Laukien added that about half of the operating profit margin expansion will come from gross margin improvements.
Q:Can you elaborate on the opportunity in proteomics and spatial entering LDT and CLIA?
A:Frank Laukien clarified that these are part of higher growth and higher margin opportunities under the company's projects accelerate, which include prior M&A activities now being integrated.
Q:What are your expectations for book-to-bill and backlog trends in 2026?
A:Frank Laukien expects book-to-bill trends to remain above 1.0, aided by easier year-over-year comparisons in Q2 through Q4. The company may use some of its high backlog but does not expect it to normalize fully in 2026.
Q:What is the product roadmap and revenue growth outlook for microbiology and diagnostics exiting 2026?
A:Frank Laukien expects the first rapid AST gram-negative, positive blood culture claim to be FDA-approved in 2026, with additional claims in clinical trials. Syndromic panels for Genius platforms are expected to roll out in Europe in late 2026 or 2027, contributing to growth in subsequent years.
Q:What is the outlook for U.S. academic and government spending in 2026?
A:Frank Laukien noted that bookings in this segment were down in the high teens in 2025. For 2026, U.S. academic and government spending is expected to remain flat or slightly down, with no significant growth anticipated.
Q:What is the revenue growth outlook for the semi business in 2026?
A:Gerald Herman stated that the semi business is expected to grow in the low single digits in 2026, following flat revenue performance in 2025.
Q:Which BSI segment is expected to lead in revenue growth in 2026?
A:Frank Laukien indicated that BioSpin will lag in revenue growth due to longer-term bookings and the absence of ultrahigh field NMR installations in 2026. B Nano, CALID, and BEST are expected to grow comparably.
Q:What are the expectations for net interest and free cash flow in 2026?
A:Gerald Herman expects net interest expense to be in the $35 million to $40 million range. Free cash flow conversion is expected to improve, building on the strong performance in Q4 2025.
Q:Review of Unclear Management Responses
A:Management avoided providing specific quantitative details on the impact of multiyear NIH funding limitations and the exact breakdown of revenue pacing improvements in 2026. Additionally, they did not clearly address the timing and magnitude of semi-related revenue recovery in Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACA GOV
BSI book
Chemspeed
GOV market
Project Accelerate
Slide revenue
action
biology NanoString
class NMR
cost saving
currency headwind
currency tailwind
decline Acquisitions
diagnostics opportunity
digit aftermarket
exchange rate
exchange tailwind
expansion basis
flow cash
generation
gigahertz NMR
gigahertz class
headwind basis
investment cash
laboratory
launch
mid digit
momentum quarter
order momentum
point benefit
point volume
press release
pricing
profile
quarter BSI
solution
tailwind non
tariff currency
BRKR Transcript
Bruker Corporation (BRKR) Q4 2025 Earnings Call Transcript
Unknown2-12
The earnings call reveals mixed signals: declining revenue and margins, but optimistic cost-saving and market recovery plans for 2026. The Q&A highlights management's confidence in improving margins and order momentum, but also notes cautious growth in key segments and unclear guidance on some factors. The absence of new partnerships or shareholder return plans, coupled with mixed financial projections, supports a neutral sentiment.
Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Bruker Corporation (BRKR) Presents at 53rd Annual Nasdaq Investor Conference Transcript
Neutral12-10
Bruker Corporation (BRKR) Q3 2025 Earnings Call Transcript
Unknown11-3
The earnings call summary indicates declining revenue, margins, and EPS for 2025, with weak financial performance and cautious guidance. The Q&A reveals management's uncertainty and lack of clarity on key issues, including future revenue growth and the impact of external factors like the government shutdown. Despite some positive expectations for 2026, such as margin expansion and cost savings, the current negative trends and lack of clear guidance suggest a negative market reaction in the short term.
BRKR Slides
BRKR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
